Principal Financial Group Inc. Boosts Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Principal Financial Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 600,488 shares of the biopharmaceutical company's stock after purchasing an additional 24,535 shares during the period. Principal Financial Group Inc. owned about 0.50% of Catalyst Pharmaceuticals worth $12,532,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of CPRX. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $65,000. KBC Group NV increased its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. Finally, Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $151,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares of the company's stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.00% of the stock is owned by insiders.

Remove Ads

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.53 during trading hours on Monday, hitting $22.36. The company's stock had a trading volume of 1,002,340 shares, compared to its average volume of 1,270,060. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 18.96, a P/E/G ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $24.64. The firm has a fifty day moving average of $22.24 and a 200-day moving average of $21.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday. Bank of America reiterated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Robert W. Baird lifted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $32.50.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.